Celltrion USA announced on March 18, 2024, the availability of ZYMFENTRA™ (infliximab-dyyb), a subcutaneous (SC) formulation of infliximab.  ZYMFENTRA™, approved by the FDA in October 2023, is the first FDA-approved SC infliximab for the treatment of moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease, with a recommended dose of 120 mg every two weeks.  Approval of ZYMFENTRA™ was based on phase III pivotal data from the LIBERTY-UC and LIBERTY-CD studies.  

[View source.]